Anticoagulants oraux directs et grossesse

  title={Anticoagulants oraux directs et grossesse},
  author={Catherine Vauzelle},
  journal={Gyn{\'e}cologie Obst{\'e}trique Fertilit{\'e} \& S{\'e}nologie }
  • C. Vauzelle
  • Gynécologie Obstétrique Fertilité & Sénologie 
1 Citations

Experience with direct oral anticoagulants in pregnancy – a systematic review

A meta-analysis displayed a higher rate of fetal loss and fetal abnormalities with DOACs use compared to LMWH, notwithstanding similar bleeding complications, and concluded thatDOACs can be safely used in pregnancy.



Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3‐year period population‐based prospective cohort study

The objective was to compare major bleeding risk of direct oral anticoagulants (DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication, using real‐world data.

Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update

A new generation of anticoagulants, the DOACs, and their reversal agents, are gaining prominence in clinical practice, having demonstrated superior efficacy and safety profiles and are poised to replace traditional anticoAGulants including warfarin.

EULAR recommendations for the management of antiphospholipid syndrome in adults

Evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults based on evidence from a systematic literature review and expert opinion were formulated and voted.

Examining the transplacental passage of apixaban using the dually perfused human placenta

The objective was to determine the rate and extent of the placental transfer of apixaban, a novel oral anticoagulant that has not been studied in pregnant patients, and its effects on maternal andfetal levels.